Introduction:
Van Heron Labs, a biotech company, has developed a technology called ai.VHL that optimizes cell cultures by tailoring nutrient and culture media formulations to the specific needs of the cells and the therapeutic products they produce. The technology uses genetic patterns and transcriptomic information to create custom supplements that address specific challenges in the bioproduction process.
- Culture media and supplement formulations are typically not specific to the cells and proteins being used in cell cultures.
- Van Heron Labs’ technology, ai.VHL, uses genetic patterns and transcriptomic information to create custom nutrient and culture media formulations that complement the metabolic needs of specific cells.
- The custom formulations optimize cell proliferation, viability, and functionality, leading to increased productivity.
- For example, ai.VHL formulations increased the proliferation and viability of a mammalian lung cell line used in COVID-19 research, and increased the specific productivity of microbial producer cells for collagen production.
- Van Heron Labs aims to eliminate manufacturing constraints and help new technologies reach end-users or patients in a more efficient and cost-effective manner.
Conclusion:
Van Heron Labs’ ai.VHL technology offers a customized and optimized approach to cell cultures, allowing for improved productivity and functionality. By tailoring nutrient and culture media formulations to specific cells and therapeutic products, the technology has the potential to overcome manufacturing constraints and accelerate the development and availability of new therapies.
